Eli Lilly & Co. (LLY) Falls as Bernie Sanders Questions Insulin Drug Price Increases
- Futures fall on Trump's protectionist address
- Qualcomm (QCOM) Calls Apple's (AAPL) Claims 'Baseless'
- Unease over Trump sends dollar to one-and-half month low
- Kate Spade (KATE) Said to Attract Interest from Coach (COH) and Michael Kors (KORS) - Bloomberg
- European stocks hit three-week low as Trump reality sets in
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Eli Lilly & Co. (NYSE: LLY) is lower after Bernie Sanders highlighted the surging cost of the company's insulin drug Humalog. Shares are down 1.8%.
Why has the price of Humalog insulin gone up 700% in 20 years? It's simple. The drug industry's greed. pic.twitter.com/SUeSbsr2Ka— Bernie Sanders (@SenSanders) November 1, 2016
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly (LLY) PT Raised to $93 at Jefferies
- Options expected to have Increasing volume
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!